Zoledronic acid hydrate Struktur

Zoledronic acid hydrate

Bezeichnung:Zoledronic acid hydrate

CAS-Nr165800-06-6

Englisch Name:Zoledronic acid hydrate

CBNumberCB5211391

SummenformelC5H12N2O8P2

Molgewicht290.1

MOL-Datei165800-06-6.mol

Zoledronic acid hydrate physikalisch-chemischer Eigenschaften

Schmelzpunkt	245 °C(dec.)
storage temp.	2-8°C
Löslichkeit	H2O: ≥2mg/mL
Aggregatzustand	powder
Farbe	white to beige
Merck	14,10187
InChIKey	FUXFIVRTGHOMSO-UHFFFAOYSA-N
CAS Datenbank	165800-06-6(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xi
R-Sätze:	36/37/38
S-Sätze:	26
WGK Germany	3
RTECS-Nr.	SZ8562450
HS Code	29332900

Gefahreninformationscode (GHS)

Zoledronic acid hydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Zoledronic acid monohydrate is an anti-resorptive agent for cancer bone metasis, also used on studies in the environmental risk asseessment of drugs from view of excretion form to environment.
Verwenden
A highly potent bisphosphonate and activator of PKC.
Trademarks
Zometa (Novartis).
Allgemeine Beschreibung
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Biologische Aktivität
Zoledronic acid (Zoledronate, CGP-4244) monohydrate is the monohydrate of Zoledronic acid (Zoledronic acid), a potent osteoclast inhibitor that inhibits small GTP-binding proteins by inhibiting enzymes of the mevalonate pathway Such as the prenylation of Ras and Rho to induce osteoclast apoptosis.
Biochem/physiol Actions
Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.
in vitro
Zoledronic Acid monohydrate (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells.Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells.Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells.Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.Zoledronic Acid monohydrate (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells.Zoledronic Acid monohydrate (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells.Zoledronic Acid monohydrate (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis.Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM.
in vivo
Zoledronic Acid monohydrate (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content.Zoledronic Acid monohydrate (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties.

Zoledronic acid hydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

165800-06-6, Zoledronic acid hydrate Verwandte Suche:

Send Inquriy